253873-06-2Relevant academic research and scientific papers
Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity
Serradji, Nawal,Martin, Marc,Bensaid, Okkacha,Cisternino, Salvatore,Rousselle, Christophe,Dereuddre-Bosquet, Nathalie,Huet, Jack,Redeuilh, Catherine,Lamouri, Aazdine,Dong, Chang-Zhi,Clayette, Pascal,Scherrmann, Jean-Michel,Dormont, Dominique,Heymans, Fran?oise
, p. 6410 - 6419 (2007/10/03)
The HIV-1 central nervous system infection leads to the onset of neurological impairments called AIDS dementia complex (ADC). PAF plays an important role in this pathology, as it is an HIV-1-induced neurotoxin produced by infected or activated macrophages
Piperazine derivatives inhibiting human immunodeficiency virus replication
-
, (2008/06/13)
The invention concerns the use of a piperazine derivative of formula (I) wherein: A and B=C═O, C═S or CR7R8with R7=H, methyl, cyano, cyanomethyl, CO2CH3or (C═O)CH3and R8=H or phenyl; R1to R6=H, OH, or C1-C5alkoxy; X represents: either C═O, O(C═O), O(C═S), O(SO2), NH(C═O), NH(C═S), NH(SO2), S(C═O) or S(C═S), then Y=NR9R10, CR9R10R11in which R9, R10and R11=H, C1-C5alkyl, C2-C5alkenyl, or C2-C5alkynyl or Y=nitrogenous heterocycle comprising 5 to 10 atoms; or X represents O, S, O(C═O)O, NH(C═O)O, or S(C═O)O, then Y=CR9R10R11with R9, R10, R11as above; or one of its pharmaceutically acceptable salts for preparing a medicine inhibiting HIV. The invention is useful for treating HIV infection.
